In addition to the data we already know and understand regarding Tovaxin's emerging safety and efficacy profile, I noted a few things from the Merriman presentation yesterday.
1. The next progress payment from Novartis will happen soon. While this progress payment is only $500k, it represents a significant milestone in the successful transfer of islet cell technology to Novartis, in a deal which is valued at up to $50 million of revenue for Opexa. This islet cell deal is wholly, completely, separate from Opexa's primary asset, Tovaxin, in which Opexa has not yet sold a single right, and retains a strong and exclusive patent position.
2. A commercial partnership for Tovaxin is proceeding well and talks are actively engaged with companies in two separate and distinct Pharma segments- those who presently have offerings in the MS pharma market and are interested in Tovaxin, and those who have strength in Neurology pharma and are interested in Tovaxin.
3. The cost of manufacturing and distribution of Tovaxin is not a constraint. These costs are well documented, will not impact margins, and are in line with the ratios found in the broader pharmaceutical market.
Market Data 
Markets 
AI
